People living with overlapping heart disease, kidney dysfunction and metabolic disorders such as obesity or diabetes face a measurably higher chance of developing cancer, according to converging evidence from large population studies in Japan and the United Kingdom. A retrospective cohort study drawing on Japan’s DeSC administrative claims database, covering April 2014 through August 2023, found that individuals at more advanced stages of cardiovascular-kidney-metabolic syndrome were diagnosed with new cancers at elevated rates. Separately, a UK Biobank analysis tracking roughly 429,555 participants showed that cardiometabolic conditions frequently preceded cancer along identifiable disease trajectories, with the sharpest risk concentrated in people whose profiles combined kidney stress, excess body fat and chronic inflammation.
Why the CKM-cancer link demands attention now
The American Heart Association formalized its cardiovascular-kidney-metabolic staging framework in 2023, creating a scale from stage 0 through stage 4 that captures how heart, kidney and metabolic problems interact and compound over time. Researchers in Japan applied that framework to a nationwide DeSC database cohort, as reported in a peer-reviewed analysis, and found that higher CKM stages at baseline tracked with greater cancer incidence during follow-up. The finding is significant because tens of millions of adults worldwide already qualify for intermediate or advanced CKM stages, yet cancer screening guidelines rarely account for this clustering of chronic conditions as a risk amplifier.
A separate prospective cohort study published in The BMJ followed participants for approximately 8.7 years and documented a dose-response pattern: the more chronic-disease markers a person carried, including diabetes, proteinuria, reduced kidney filtration and cardiovascular indicators, the higher their rates of both cancer incidence and cancer-related death. That gradient suggests the relationship is not simply a matter of one disease occasionally accompanying another. Instead, the accumulation of metabolic and organ damage appears to create biological conditions that favor tumor development.
One hypothesis worth testing is whether serial advancement through CKM stages accelerates cancer risk primarily through shifts in the gut microbiome. Microbiome-related pathways are among the shared mechanisms identified in a review published in Nature Reviews Cardiology, alongside chronic inflammation, oxidative stress, metabolic dysregulation, clonal hematopoiesis and cellular senescence. If microbiome-driven metabolite changes do amplify systemic inflammation as CKM worsens, adding stool metagenomics to existing longitudinal studies such as the UK Biobank or DeSC follow-up visits could isolate that pathway. No current study has paired sequential CKM staging with serial microbiome sampling and cancer endpoints in the same cohort, leaving this mechanism plausible but unproven.
Converging evidence from three population-scale datasets
The strongest evidence comes from studies that approached the question from different angles and arrived at compatible conclusions. The Japan DeSC study used the AHA’s 2023 CKM framework to classify individuals at baseline, then tracked new cancer diagnoses through administrative claims records. The UK Biobank analysis, published in a recent Nature Communications report, used multistate models and multi-omics signatures to map how people transition from cardiometabolic disease to cancer, multimorbidity and death. Both studies point to the same core finding: cardiometabolic burden is not merely a parallel health problem but a precursor state that raises the probability of a cancer diagnosis.
A third UK Biobank analysis used data-driven metabolic subgrouping and identified a specific cluster defined by kidney stress, high adiposity and inflammation. That subgroup carried not only elevated rates of ischemic heart disease but also higher cancer risk and higher mortality. The overlap matters because it shows that the danger is concentrated in a recognizable metabolic profile, not spread evenly across everyone with any single chronic condition. For clinicians, this clustering offers a practical way to flag patients who may benefit from earlier or more intensive cancer surveillance.
The biological explanation for this overlap centers on a handful of shared mechanisms. A review in Nature Reviews Cardiology cataloged modifiable risk factors common to both cardiovascular disease and cancer: hypertension, diabetes, obesity, smoking, poor diet, physical inactivity and social determinants of health. At the cellular level, chronic inflammation and insulin resistance create an environment where damaged cells are more likely to survive and proliferate. The National Cancer Institute has separately documented how obesity drives elevated insulin and IGF-1 levels, sustains chronic inflammation and increases risk for multiple cancer types, reinforcing the same mechanistic picture from a government research perspective.
Gaps in the data and what patients should watch for
Several important questions remain open. The Japan DeSC study provides aggregate incidence patterns but has not released individual-level claims records or detailed cancer subtype counts for independent replication. The UK Biobank multistate models reference multi-omics signatures, yet the raw metabolite and genetic datasets needed to reproduce transition probabilities are not fully accessible for all investigators. No study in the current evidence base supplies population-attributable risk fractions that link specific CKM stages to preventable cancers across racially diverse populations. That limitation is crucial, because both CKM burden and cancer incidence vary substantially by ancestry, environment and socioeconomic status.
Review papers have also highlighted the lack of randomized trials that treat CKM burden itself as a modifiable cancer risk factor. Existing prevention studies typically focus on single endpoints-such as cardiovascular events or glucose control-without systematically tracking incident cancers over long horizons. Without such trials, it remains uncertain how much of the observed cancer excess in advanced CKM stages could be reversed through intensive risk-factor management, versus how much reflects irreversible damage accrued earlier in life.
For patients, the immediate implication is not panic but vigilance. People living with combinations of obesity, type 2 diabetes, chronic kidney disease, hypertension or established cardiovascular disease should recognize that these conditions may collectively nudge their cancer risk upward. That does not mean everyone with CKM features will develop cancer, nor that cancer is inevitable once a certain stage is reached. It does mean that staying current with age-appropriate screening for colorectal, breast, cervical, lung and prostate cancers becomes even more important when multiple cardiometabolic problems coexist.
Patients can also work with clinicians to address modifiable drivers that sit at the intersection of CKM and cancer risk. Smoking cessation, sustained weight management, improved diet quality, regular physical activity and tighter blood pressure and glucose control are already cornerstones of cardiovascular prevention. The emerging CKM-cancer literature suggests these same steps may, over time, help lower the probability of certain malignancies as well. While definitive proof from randomized cancer-endpoint trials is lacking, the balance of evidence supports acting now on risks that are already well established for other outcomes.
On the research side, the next phase will likely involve integrating CKM staging into large-scale cancer epidemiology and trial design. That could mean stratifying participants by CKM stage at enrollment, embedding microbiome and multi-omics sampling into follow-up, and explicitly modeling cancer as a downstream state in cardiometabolic disease trajectories. Such designs would clarify which components of CKM matter most for which cancers, and whether aggressive early intervention can bend those trajectories.
Until those answers arrive, the message from Japan’s claims data, the UK Biobank analyses and mechanistic reviews is broadly consistent: when heart, kidney and metabolic disorders cluster, cancer risk tends to rise. Recognizing that pattern early offers a chance to tighten prevention, tailor screening and, potentially, change the course of disease before it converges on malignancy.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
